AlissaA.Thomas,MD;CameronW.Brennan,MD;LisaM.DeAngelis,MD;AntonioM.Omuro,MD IMPORTANCE Glioblastoma is the most common primary malignant brain tumor, but despite multimodal treatment with surgery, radiotherapy, and temozolomide chemotherapy, the prognosis is poor, with a median survival of 16 to 19 months and poor quality of life throughout the disease course. New treatments are needed. EVIDENCE REVIEW  Articles were identified through a search of PubMed references from March

Saritha Krishna ,  Abrar Choudhury ,  Michael B. Keough ,  Kyounghee Seo ,  Lijun Ni ,  Sofia Kakaizada ,  Anthony Lee ,  Alexander Aabedi ,  Galina Popova ,  Benjamin Lipkin ,  Caroline Cao ,  Cesar Nava Gonzales ,  Rasika Sudharshan ,  Andrew Egladyous ,  Nyle Almeida ,  Yalan Zhang ,  Annette M. Molinaro ,  Humsa S. Venkatesh ,  Andy G. S. Daniel ,  Kiarash Shamardani ,  Jeanette Hyer ,  Edward F. Chang ,  Anne Findlay ,  Joanna J. Phillips ,  Shawn L. Hervey-Jumper   Natu

Helen Kim, PhD1,2 ;  Jeffrey Nelson, MS1 ;  Charles E. McCulloch, PhD2  et al 2025년 10월6일 JAMA Neurol . Published online: October 6, 2025. Doi: 10.1001/jamaneurol.2025.3581   Abstract   Importance   Annual rates of first intracranial hemorrhage (ICH) from unruptured brain arteriovenous malformations (AVMs) are often quoted as 2% to 4% in clinical practice. Precise estimates and risk factors are unavailable to inform treatment decisions. Objectives   To provide estimates of ra

Intensive Care Med, Volume 51, pages 2199-2212, (2025) Conference Repors and Expert Panel, Published: 03 November 2025 Doi: 10.1007/s00134-025-08186-4   Abstract   Intensive care unit acquired weakness (ICUAW) is common in critically ill patients, contributing to substantial morbidity. Major trials and novel mechanistic findings published over the past years have advanced knowledge for the prevention and treatment of ICUAW. To streamline future research priorities, a multinat

Intensive Care Med, Volume 51, pages 2213-2288, (2025) Conference Repors and Expert Panel, Published: 22 October 2025 Doi: 10.1007/s00134-025-08117-3   Abstract     The European Resuscitation Council (ERC) and the European Society of Intensive Care Medicine (ESICM) have collaborated to produce these post-resuscitation care guidelines for adults, which are based on the International Consensus on Cardiopulmonary Resuscitation Science with Treatment Recommendations (CoSTR) pubis

Lauren R. Schaff, MD 1,2 ;  Ingo K. Mellinghoff, MD 1,2,3,4   JAMA Published Online: February 21, 2023 2023;329;(7):574-587. doi:10.1001/jama.2023.0023 Abstract Importance   Malignant primary brain tumors cause more than 15 000 deaths per year in the United States. The annual incidence of primary malignant brain tumors is approximately 7 per 100 000 individuals and increases with age. Five-year survival is approximately 36%. Observations   Approximately 49% of malignant brain

Alessandro Salvalaggio, MD a,b,c  ∙  Lorenzo Pini, PhD b  ∙  Prof Alessandra Bertoldo, PhD c,d  ∙  Prof Maurizio Corbetta, MD a,b,c,e   maurizio.corbetta@unipd.it   Publication History: Published July 2024 DOI:  10.1016/S1474-4422(24)00160-1 External Link Also available on  ScienceDirect External Link Copyright: © 2024 Elsevier Ltd. All rights reserved.   Summary Despite substantial advances in cancer treatment, for patients with glioblastoma prognosis remains bleak. The emer

Michelle L. Mauermann, MD1 ;  Nathan P. Staff, MD, PhD1 2025년 11월 17일 JAMA Published Online: November 17, 2025 DOI: 10.1001/jama.2025.19400 Abstract Importance   Peripheral neuropathy, defined as damage to peripheral nerves, affects approximately 1% of adults worldwide. More than 200 causes of peripheral neuropathy exist, with symptoms ranging in severity from mild toe numbness to debilitating symptoms that can require a wheelchair. Diabetes is the most common cause of neurop

GBD 2021 US CNS Cancer Collaborators 2025년 11월3일 JAMA Neurol . Published online: November 3, 2025. Doi: 10.1001/jamaneurol.2025.4286 Abstract   Importance   Primary brain and central nervous system cancer (collectively referred to as CNS cancer) comprises 2% of all human cancers and poses significant health and economic challenges in the United States. Objectives   To analyze CNS cancer burden in the US, stratified by time, location (state and division), sex, age group, and S

Chengcheng Guo, MD, PhD 1 ;  Qunying Yang, MD, PhD 1 ;  Pengfei Xu, MD, PhD 1 Meiling Deng, MD, PhD 2 ;  Taipeng Jiang, MD, PhD 3 ;  Linbo Cai, MD, PhD 4 ;  Jibin Li, MD, PhD 5 ;  Ke Sai, MD, PhD 1 ;  Shaoyan Xi, MD, PhD 6 ;  Hui Ouyang, MD, PhD 7 ;  Mingfa Liu, MD, PhD 8 ;  Xianming Li, MD, PhD 9,10 ;  Zihuang Li, MD, PhD 9,10 ;  Xiangrong Ni, MD, PhD 1 ;  Xi Cao, BSN 1 ;  Cong Li, MD, PhD 11,12 ;  Shaoxiong Wu, MD, PhD 2 ;  Xiaojing Du, MD, PhD 2 ;  Jun Su, MD, PhD 13 ;  Xi

JAMA 2025. Ranzani et al.-30년 만의 전면 개정

Otavio T. Ranzani, MD, MSc, PhD 1,2,3 ;  Mervyn Singer, MD 4 ;  Jorge I. F. Salluh, MD, PhD 5 et al 2025년 10월 29일 JAMA Published Online: October 29, 2025 DOI: 10.1001/jama.2025.20516 Abstract Importance   Acute dysfunction of vital organs is the hallmark of critical illness. The Sequential Organ Failure Assessment (SOFA) score, the most widely adopted approach to describe organ dysfunction, has not been updated in 30 years and therefore may not appropriately capture current c

Prof Martin J van den Bent, MD a   m.vandenbent@erasmusmc.nl  ∙  Marjolein Geurts, MD a  ∙  Pim J French, PhD a  ∙ ...

The VasCog-2-WSO Criteria Consortium 2025년09월16일 JAMA Neurol . Published online: September 16, 2025. Doi: 10.1001/jamaneurol.2025.3242...

Mark G.  Luciano, M.D., Ph.D. et al. 2025년 9월 16일 N Engl J Med DOI: 10.1056/NEJMoa2503109 Abstract   Background Idiopathic...

Alessandro Salvalaggio, MD, PhD 1,2 ;  Lorenzo Pini, PhD 1,2 ;  Matteo Gaiola, MD 1 et al JAMANeurol.2023;80(11):1222-1231.doi:10.1001/j...

Michaël Chassé, MD, PhD1,2,3 ;  Jai Jai Shiva Shankar, MD, MSc4,5 ;  Dean A. Fergusson, PhD6,7 ; et al 2025년06월13일 JAMA Neurol...

Tianqi Xiao, MD1,2 ;  Pranav Kumar, BA1,2 ;  Mina Lobbous, MD, MSPH2,3 ; et al   2025년09월02일 JAMA Neurol . Published online: September 2,...

Daniele Urso, MD, MPH1,2 ;  Stefano Giannoni-Luza, MD, MPH1 ;  Carol Brayne, MD, MSc3 ; et al 2025년09월08일 JAMA Neurol . Published online:...

Qingyuan Liu, MD1 ;  Xin Nie, MD1 ;  Mervyn D. I. Vergouwen, MD, PhD2 ; et al 2025년09월08일 JAMA Neurol . Published online: September 8,...

Adam S. Arthur, MD, MPH1 ;  Babak S. Jahromi, MD2 ;  Paul S. Saphier, MD3,4 et al 2025년 9월 2일 JAMA Neurol . September 2, 2025 DOI:...

Adam M Sonabend   1 ,  Andrew Gould   2 ,  Christina Amidei   2 ,  Rachel Ward   2 ,  Karyn A Schmidt   2 ,  Daniel Y Zhang   3 , ...

Yu Zhou, MD1,2 ;  Lei Zhang, MD1 ;  Fabiano Cavalcante, MD, MSc3 ; et al 2025년 8월 11일 JAMA Neurol . August 11, 2025 DOI:...

Prof Sujay Vora, MD a ∙  Deanna Pafundi, PhD d ∙  Molly Voss, BS e ∙  Matthew Buras, MS e ∙  Jonathan Ashman, MD a ∙  Prof Bernard...

Matthew J. Summers, BSc, MDiet1,2 ;  Lee-anne S. Chapple, PhD1,2,3,4 ;  Amalia Karahalios, PhD5,6 ; et al 2025년 06월11일 JAMA. Published...

Georgios S. Sioutas, MD1 ;  William Mualem, MD1 ;  John Reavey-Cantwell, MD, MBA, MS1 ; et al 2025년07월14일 JAMA Neurol . Published online:...

Annette M. Molinaro, PhD; Shawn Hervey-Jumper, MD; Ramin A. Morshed, MD; Jacob Young, MD; Seunggu J. Han, MD; Pranathi Chunduru, MS;...

: a randomised, open-label, phase 3   trial Ulrich Herrlinger*, Theophilos Tzaridis*, Frederic Mack, Joachim Peter Steinbach, Uwe...

Esmée Verburgt, MSc1 ;  Lina Fellah, MSc1 ;  Merel S. Ekker, MD, PhD1 ; et al 2025년04월 14일 JAMA Neurol .    2025;82(6):597-604 DOI:...

David A. Reardon, MD1 ;  Alba A. Brandes, MD2 ;  Antonio Omuro, MD3 ; et al Paul Mulholland, PhD4 ;  Michael Lim, MD5 ;  Antje Wick, MD6...